1. Kidney Cancer: Highlights from 2006
Francesco Montorsi 
European Urology Supplements 
Volume 6, Issue 12, Pages (July 2007)
DOI: /j.eursup
Copyright © 2007 European Association of Urology Terms and Conditions

2. Fig. 1
The size of renal cell carcinomas (RCCs) correlates with advanced stage (≥ pT3a) [9].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

3. Fig. 2
Although, a gradual increase in the percentage of partial nephrectomy (PN) has been observed in 1988–1989 and 2000–2001, it remains a relatively uncommon procedure, even in small size renal cell carcinomas (RCCs) [11].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

4. Fig. 3
Both operation time and estimated blood loss are significantly higher for laparoscopic partial nephrectomy (LPN) compared to laparoscopic cryoablation (LCA) [18].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

5. Fig. 4
Results from interactive voting indicate that partial nephrectomy (PN), either open or laparoscopic, is the favoured treatment option for the given case (details are outlined in the text). Surprisingly, open or laparoscopic radical nephrectomy (RN) is still a frequently chosen treatment strategy. None of the participants chose another minimally invasive (MI) technique as treatment option.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

6. Fig. 5
The objective response rate in patients with advanced renal cell carcinoma is higher after sunitinib treatment compared with interferon-α (IFN-α) treatment [30].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions

7. Fig. 6
Temsirolimus (Temsr) treatment of patients with advanced renal cell carcinoma generates a significant increase in median survival compared to interferon-α (IFN-α) treatment, whereas no significant increase was observed with the combination therapy (Temsr+IFN-α) [39].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © 2007 European Association of Urology Terms and Conditions